New equations, lower targets, and mandatory Lp(a) testing.
A Game-Changer in Cardiovascular Prevention
After nearly a decade, the ACC/AHA’s newly released 2026 Multisociety Guideline on Dyslipidemia is reshaping how clinicians think about cholesterol, risk, and prevention. Published on March 13, 2026, in both JACC and Circulation, this much-anticipated overhaul, crafted by 11 professional societies, reflects the best evidence through late 2024 and responds to the evolving landscape of lipid management.
It’s no longer just about “blood cholesterol,” as the new guideline targets dyslipidemias (plural). This broader focus now includes conditions like hypertriglyceridemia and elevated Lp(a) (lipoprotein(a)), alongside the classic LDL cholesterol.
Out with the Old, In with the PREVENT
The Pooled Cohort Equations (PCE) are out. In their place: the PREVENT-ASCVD equations.
- Why the shift? The old model was overestimating 10-year cardiovascular risk by a staggering 40–50%, leading to over-treatment and muddying prevention strategies.
- The PREVENT difference: It offers both 10-year and 30-year risk estimates for adults aged 30–79 without known ASCVD and with LDL-C between 70–189 mg/dL.
- Risk categories redefined:
- Low: <3% (10-year)
- Borderline: 3–5%
- Intermediate: 5–10%
- High: ≥10%
A new CPR framework (Calculate, Personalize, Reclassify, and Reassess) guides clinicians through primary prevention.
Targets Return, And They’re Lower Than Ever
If you’ve found the target-free approach of the 2018 guidelines difficult to explain to patients, the committee heard that feedback. Explicit LDL-C goals are back, stratified by risk:
- Very high-risk ASCVD (secondary prevention, highest risk): goal less than 55 mg/dL
- Clinical ASCVD, not very high-risk (secondary prevention): goal less than 70 mg/dL
- High-risk primary prevention (diabetes or elevated 10-year risk): goal less than 70 mg/dL
- Lower-risk primary prevention (no significant risk factors): goal less than 100 mg/dL
These targets give clinicians and patients a concrete destination, improving shared decision-making and providing a clear benchmark for treatment intensification when goals aren’t met.
Lp(a): The One Test Every Adult Needs
For the first time, every adult should have their Lp(a) measured at least once. No more selective screening. Why? The reason is because Lp(a) is genetic and stable over time. Having an elevated Lp(a) correlates to a higher ASCVD risk, even if other factors seem controlled. While dedicated therapies are still in development, knowing Lp(a) status means clinicians can treat the rest of the lipid profile more aggressively.
ApoB: The Next-Level Risk Marker
If LDL-C and non-HDL-C targets are reached but questions remain, ApoB is now recommended, especially for patients with:
- Triglycerides >200 mg/dL
- Diabetes
- LDL-C <70 mg/dL
ApoB provides a more precise measure of atherogenic particle burden, helping clinicians spot hidden cardiovascular risk.
Early Action: Prevention Starts at 30
This guideline takes a notably lifespan-oriented approach. Lipid-lowering therapy can now be considered starting at age 30 for adults at high long-term risk or with substantially elevated LDL-C. Atherosclerosis is a decades-long process, and cumulative exposure to atherogenic lipoproteins matters. Earlier intervention is especially relevant for patients with:
- Familial hypercholesterolemia
- LDL-C of 160 mg/dL or greater
- A strong family history of premature ASCVD
Special population guidance is also available from the AHA for pediatric, geriatric, and women’s health clinicians.
Still Unsure? Let Calcium Scoring Decide
Coronary artery calcium scoring retains its role as a risk reclassifier for patients in the borderline or intermediate range where the treatment decision is genuinely uncertain. The guideline recommends CAC for men aged 40 and older and women aged 45 and older, noting that both the absolute score and the age-, sex-, and race-standardized percentile carry prognostic weight.
The Bottom Line: Actionable, Personalized, and Preventive
As always, lifestyle modification remains the foundation. The AHA’s Life’s Essential 8 framework continues to carry a Class 1A recommendation as a cardiovascular risk reduction strategy.
But the 2026 guideline is more actionable than its predecessor. It gives clinicians explicit targets to work toward, better tools to identify who needs treatment and when, and a mandate to start those conversations earlier. For those managing complex lipid disorders or building structured prevention programs, it’s worth a close read.
- Lifestyle first: The AHA’s Life’s Essential 8 remains a top recommendation.
- Better risk tools, clearer targets, and earlier intervention empower clinicians and patients alike.
- Full resources: Find the guideline text, patient summaries, and the new PREVENT calculator at professional.heart.org.
The 2026 guideline marks a bold step forward in personalized care. For clinicians and anyone managing cholesterol, these changes are essential reading.
Sources
Blumenthal R, Morris P, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. Published online March 13, 2026. doi:10.1016/j.jacc.2025.11.016
Blumenthal R, Morris P, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. Circulation. Published online March 13, 2026. doi:10.1161/CIR.0000000000001423
2026 Dyslipidemia Guideline-at-a-Glance. J Am Coll Cardiol. Published online March 18, 2026. doi:10.1016/j.jacc.2026.02.4872
American Heart Association. 2026 Guideline on the Management of Dyslipidemia — Professional Resources. professional.heart.org. Published March 13, 2026. Available at: https://professional.heart.org/en/science-news/2026-guideline-on-the-management-of-dyslipidemia
National Lipid Association. 2026 ACC/AHA/Multisociety Dyslipidemia Guideline Released. lipid.org. Published March 13, 2026. Available at: https://www.lipid.org/nla/2026-accahamultisociety-dyslipidemia-guideline-released
American College of Cardiology. ACC/AHA Issue Updated Guideline for Managing Lipids, Cholesterol. acc.org. Published March 13, 2026. Available at: https://www.acc.org/about-acc/press-releases/2026/03/13/18/01/accaha-issue-updated-guideline-for-managing-lipids-cholesterol
